Israel’s Pluristem Shows Promise with High Survival Rates
A Haifa-based regenerative medicine company that has been treating COVID-19 patients with its biological therapeutic products reported that 75% of those treated were off any mechanical ventilation within 28 days.
Last month, Pluristem began testing its PLX cells on patients with COVID-19 in hopes of reducing the effects of the virus-induced pneumonia or pneumonitis and leading to a better prognosis.
Eighteen patients were treated under a compassionate use program in Israel, and the FDA single Patient Expanded Access Program. They were all in intensive care units, on invasive mechanical ventilation and suffered from Acute Respiratory Syndrome at the time of treatment.
So far, eight of the patients have completed a 28-day follow up period, with a survival rate of 87.5%.
In the New York area, only 3.3% (38 out of 1,151) patients who required mechanical ventilation during April and May were discharged alive, as reported by The Journal of the American Medical Association.